Want to join the conversation?
Biotechnology company $GILD said that the authorization to market the once-daily single tablet regimen Genvoya for the treatment of HIV-1 infection in adults & adolescents has been granted by the European Commission. This authorization is supported by the 48-week data from two ongoing Phase 3 studies among 1,733 treatment-naive adult patients.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.